Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

995
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
995
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

259
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
259
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

213
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
213
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

453
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
453
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the slope: prognostic utility of the VE/VCO<sub>2</sub> intercept in chronic heart failure.

Open heart·2026
Same author

Assessment of double anaerobic threshold in trained subjects.

Respiratory physiology & neurobiology·2026
Same author

A modified Canadian Syncope Risk Score for emergency department use.

Internal and emergency medicine·2026
Same author

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk score.

Vascular pharmacology·2025
Same author

Pathophysiology of Pulmonary Arterial Hypertension: Focus on Vascular Endothelium as a Potential Therapeutic Target.

International journal of molecular sciences·2025
Same author

The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice.

Reviews in cardiovascular medicine·2025

Related Experiment Video

Updated: Feb 19, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Liver disease and heart failure: Back and forth.

Michele Correale1, Nicola Tarantino2, Rossella Petrucci2

  • 1Ospedali Riuniti University Hospital, Foggia, Italy.

European Journal of Internal Medicine
|November 5, 2017
PubMed
Summary

Physicians must understand the complex heart-liver interactions to effectively treat patients. This review details the mechanisms and clinical implications of this vital cardio-hepatic cross-talk.

Keywords:
Cardiovascular diseaseLiver diseaseReview

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.3K

Related Experiment Videos

Last Updated: Feb 19, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.3K

Area of Science:

  • Cardiology
  • Hepatology
  • Internal Medicine

Background:

  • Heart and liver diseases frequently coexist and impact each other.
  • Systemic conditions can affect both organs, necessitating a holistic approach.
  • Understanding the heart-liver axis is crucial for optimal patient management.

Purpose of the Study:

  • To review the mechanisms and evidence of the complex interactions between the heart and liver.
  • To summarize clinical presentations, diagnostic markers, and therapeutic considerations.
  • To highlight the reciprocal effects of diseases and treatments on both organs.

Main Methods:

  • Literature review of existing evidence on heart-liver interactions.
  • Discussion of pathophysiology, clinical manifestations, and diagnostic tools.
  • Analysis of drug-induced cardio-hepatotoxicity and post-transplantation effects.

Main Results:

  • Heart failure can lead to congestive and ischemic hepatopathy.
  • Liver diseases, such as cirrhosis, can cause cirrhotic cardiomyopathy.
  • Various conditions and medications can simultaneously affect both heart and liver.
  • Inflammatory mediators and metabolic substrates form a heart-liver axis.

Conclusions:

  • The heart and liver are intricately linked, with bidirectional influences.
  • Recognizing and managing cardio-hepatic interactions is essential for clinical practice.
  • Further research into this axis can improve therapeutic strategies for related diseases.